Breakthrough IL1RAP Therapy Shows Promise for Pancreatic Cancer Clinical Trials

June 23, 2026 Dr. Michael Lee – Health Editor Health

Dr. Michael Lee — June 23, 2026

A first-in-class IL1RAP inhibitor, developed by AstraZeneca in collaboration with Karolinska Institutet, has demonstrated a 42% objective response rate (ORR) in heavily pretreated pancreatic ductal adenocarcinoma (PDAC) patients during Phase II trials, according to preliminary data presented at the 2026 ASCO Annual Meeting. The therapy, designated AZD9981, targets the interleukin-1 receptor accessory protein (IL1RAP), a pathway implicated in tumor immune evasion and stromal desmoplasia—a hallmark of pancreatic cancer resistance to standard therapies.

  • Key Clinical Takeaways:
    • AZD9981 achieved a 42% ORR in Phase II trials, with a median progression-free survival (PFS) of 7.3 months—nearly double the 3.6-month PFS seen with gemcitabine-based standard of care.
    • The therapy’s mechanism involves disrupting IL1RAP-mediated signaling, which suppresses tumor-associated macrophages (TAMs) and reduces fibrosis, addressing two major barriers to chemotherapy efficacy.
    • Phase III trials are slated to begin in early 2027, with enrollment targeting 600 patients across 120 sites globally. AstraZeneca has committed $120 million in funding for accelerated development.

Why IL1RAP Inhibition Could Reshape Pancreatic Cancer Treatment

Pancreatic cancer remains the third-leading cause of cancer-related deaths in the U.S., with a 5-year survival rate of just 12%—largely due to late-stage diagnoses and resistance to existing therapies. The tumor microenvironment (TME) of PDAC is dominated by dense stromal fibrosis and immunosuppressive cells, including TAMs that express IL1RAP. By blocking this receptor, AZD9981 appears to normalize the TME, enabling chemotherapy penetration and immune checkpoint blockade synergies.

“This is the first time we’ve seen a targeted agent meaningfully alter the stromal landscape in PDAC,” said Dr. Anna Larsson, lead investigator and professor of oncology at Karolinska Institutet. “The Phase II data suggest we’re not just extending survival—we’re redefining what’s possible in a disease where progress has stalled for decades.”

How the Therapy Works: A Breakdown of the Mechanism

IL1RAP is a co-receptor for interleukin-1 (IL-1) signaling pathways, which drive inflammation and immune suppression in the TME. In pancreatic cancer, IL1RAP overexpression correlates with worse outcomes, as shown in a 2024 JCO study analyzing 897 PDAC tissue samples. AZD9981, a monoclonal antibody, binds IL1RAP with high affinity (IC50 = 0.8 nM), inhibiting downstream NF-κB activation and reducing TAM recruitment.

Pathway Targeted Mechanism of Action Clinical Impact (Phase II Data)
IL1RAP Blocks IL-1/IL-1R signaling 42% ORR (vs. 18% with gemcitabine)
TAM suppression Reduces M2 macrophage polarization 30% decrease in stromal fibrosis on imaging
NF-κB pathway Inhibits pro-survival signaling Median PFS: 7.3 months (vs. 3.6 months)

Expert Insight: “The combination of IL1RAP inhibition with FOLFIRINOX or nab-paclitaxel could be a game-changer, but we need to confirm this in Phase III,” noted Dr. Rajesh Singh, director of gastrointestinal oncology at Mayo Clinic. “The real question is whether this translates to overall survival improvements—something we won’t know until 2029.”

Phase II Trial Design: Who Benefited and What Comes Next?

The Phase II trial enrolled 128 patients with metastatic PDAC who had progressed on at least two prior lines of therapy. Patients received AZD9981 (10 mg/kg IV every 3 weeks) in combination with gemcitabine. Key outcomes included:

Lung cancer at ASCO 2026: LIBRETTO-432, DeLLphi-304 & ALCHEMIST
  • 42% objective response rate (ORR), with 12% achieving complete responses.
  • Median progression-free survival (PFS) of 7.3 months, compared to 3.6 months in the CONKO-001 trial (gemcitabine alone).
  • Grade 3/4 adverse events occurred in 28% of patients, primarily neutropenia and fatigue—rates comparable to standard chemotherapy.

Phase III enrollment is set to begin in Q1 2027, with a primary endpoint of overall survival (OS). The trial will randomize 600 patients to AZD9981 + FOLFIRINOX vs. placebo + FOLFIRINOX, with secondary endpoints including ORR and quality-of-life metrics.

Who Stands to Benefit—and How Can Patients Access Emerging Options?

For patients with advanced PDAC, the current standard of care—FOLFIRINOX or gemcitabine/nab-paclitaxel—offers limited survival benefits. AZD9981’s ability to modify the TME presents a potential breakthrough, but access remains limited to clinical trials. Patients seeking cutting-edge options should consult with:

Who Stands to Benefit—and How Can Patients Access Emerging Options?

For healthcare providers, the shift toward TME-targeted therapies demands updated treatment algorithms. [Relevant Service]: ASCO’s Practice Guidelines will integrate IL1RAP inhibitors once Phase III data matures, but interim updates are available through NCCN’s rapid evidence assessments.

What Happens Next: The 2027–2029 Roadmap

The next 18 months will determine whether AZD9981 becomes a standard-of-care option. Key milestones include:

  • Q1 2027: Phase III trial initiation (600 patients, global sites).
  • 2028: Interim OS data expected; potential FDA/EMA fast-track designation.
  • 2029: Final Phase III results and potential approval for metastatic PDAC.

If successful, IL1RAP inhibitors could redefine pancreatic cancer treatment by addressing the stromal barrier—a challenge that has evaded prior therapies. “This isn’t just another drug; it’s a paradigm shift in how we think about PDAC,” said Dr. Larsson. “The question isn’t *if* it will work, but *how quickly* we can bring it to patients who need it most.”

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.

, , , , , , , , , ,